This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1276 entries already.
In the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.
Scotland’s biotechnology sector is celebrating a major milestone with the launch of the nation’s first open-access 300-litre fermenter – a state-of-the-art piece of equipment that will support early-stage companies to develop bio-based products at scale.
German researchers have identified a promising new target to stop the inflammatory response in ulcerative colitis—a breakthrough that could help prevent the progression to colorectal cancer. Phase II clinical trials of a corresponding monoclonal antibody, licensed by Roche, are expected to begin soon.
The European Commission has promised to create a new public-private fund to bridge the ‘valley of death’ phase for technology companies facing expansion. In addition, the EU wants to reduce its lag in the number of technology unicorns compared to the United States and China with a start-up and scale-up strategy.
Foodtech startup Norwegian Mycelium A/S has raised €1.25m in a financing round led by Nippon Beet Sugar Manufacturing Co., Ltd. (Nitten), Japan’s largest beet sugar producer, to scale-up its mycoprotein platform.
For nearly two decades, Roche AG has been searching for a next-generation sequencing method in personalised medicine to overcome the limitations of short read lengths in existing sequencing technologies. Following beta testing, the company plans to launch its new Sequencing by Expansion (SBX) technology commercially next year.
C4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor. This payment is based on a licence agreement from 2021, under which the British company could receive up to €414m, including royalties.
Pharmacologists at the University of Göttingen, Germany, have reported a simple way to target and silence individual mitochondrial mRNAs in vivo.
British company Wildcat Laboratory Solutions Ltd and Hamburg-based mo:re GmbH have received the New Product Award from the Society for Laboratory Automation and Screening (SLAS) in recognition of new technologies with potential to drive industry transformation. The award for the most promising start-up was conferred upon Swiss firm Oryl Photonics SA.
Organised by the Society for Laboratory Automation and Screening (SLAS), SLAS Europe currently is taking place in Hamburg from 20–22 May. As part of a special series, European Biotechnology Magazine is profiling twelve of the most innovative exhibiting SMEs supported under the SLAS AveNew programme. Among them is US-based ThirdLaw Molecular Inc.